NOV
45
2
VFC
56
6
CTAS
36
8
CNP
59
17
BAX
38
2
PCG
59
9
MMM
35
3
MA
60
5
SJM
17
5
HBAN
47
7
AMP
43
2
PEG
53
7
CINF
24
-8
UNP
38
5
CVS
27
2
DFS
64
4
WMB
58
3
MTCH
62
22
EIX
61
8
ZBH
69
15
NOV
45
2
VFC
56
6
CTAS
36
8
CNP
59
17
BAX
38
2
PCG
59
9
MMM
35
3
MA
60
5
SJM
17
5
HBAN
47
7
AMP
43
2
PEG
53
7
CINF
24
-8
UNP
38
5
CVS
27
2
DFS
64
4
WMB
58
3
MTCH
62
22
EIX
61
8
ZBH
69
15
Financhill
Back

Novo Nordisk AS Quote, Financials, Valuation and Earnings

How to Turn the AI Energy Crisis into BIG Profits

And investors who move now into one technology could make a whole lot of money.
Sell
23

NVO
Novo Nordisk AS

Last Price:
$85.00
Seasonality Move:
6.92%

7 Day Trial

ALL ACCESS PASS

$ 7

FREE REPORT: 2025 Gold Price Outlook

Get Your Copy of "2025 Gold Forecast: A Perfect Storm for Demand" Here.

Novo Nordisk AS Price Quote

$85.00

Novo Nordisk AS Key Stats

Sell
23
Novo Nordisk AS (NVO) is a Sell
Day range:
$81.50 - $86.53
52-week range:
$81.50 - $148.15
Dividend yield:
1.7%
P/E ratio:
31.44
P/S ratio:
9.65
P/B ratio:
20.91%
Volume:
53.4M
Avg. volume:
6.9M
1-year change:
-16.1%
Market cap:
$377.5B
Revenue:
$33.7B
EPS:
$3.09

How Much Does Novo Nordisk AS Make?

Data Unavailable

Is Novo Nordisk AS Growing As A Company?

Data Unavailable

Novo Nordisk AS Stock Price Performance

  • Did Novo Nordisk AS Stock Go Up Last Month?
    Novo Nordisk AS share price went down by -19.26% last month
  • Did NVO's Share Price Rise Over The Last Year?
    NVO share price fell by -16.1% over the past 1 year

What Is Novo Nordisk AS 52-Week High & Low?

Novo Nordisk AS Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Novo Nordisk AS?

Data Unavailable

Is Novo Nordisk AS Cash Flow Positive?

Data Unavailable

Novo Nordisk AS Return On Invested Capital

Data Unavailable

Novo Nordisk AS Earnings Date & Stock Price

Novo Nordisk AS Competitors

  • Who Are Novo Nordisk AS's Competitors?
    Below is a list of companies who compete with Novo Nordisk AS or are related in some way:
    • Akari Therapeutics PLC (AKTX)
    • Amgen Inc (AMGN)
    • Ascendis Pharma AS (ASND)
    • Evaxion Biotech AS (EVAX)
    • Viking Therapeutics Inc (VKTX)

Novo Nordisk AS Dividend Yield

Data Unavailable

Novo Nordisk AS Analyst Estimates

YoY Growth Past Surprise
EPS: 23.52% 3.93%
Revenue: 22.53% -0.31%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 2
Sell Recommendations: 1
Price Target: 122.11
Upside from Last Price: 43.66%

Major Shareholders

Data Unavailable